Medicare Enrolled

Dr. Behnam Ebrahimi, M.D.

Hematology & Oncology · Rancho Cucamonga, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
12577 NAPLES WAY, Rancho Cucamonga, CA 91739
7142812993
In practice since 2006 (19 years)
NPI: 1033165139 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ebrahimi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ebrahimi? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ebrahimi

Dr. Behnam Ebrahimi is a hematology & oncology specialist in Rancho Cucamonga, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Ebrahimi performed 2,216 Medicare services across 650 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ebrahimi received a total of $307,477 from 47 pharmaceutical and/or device companies across 407 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ebrahimi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 40% volume in CA $307,477 industry payments

Medicare Practice Summary

Medicare Utilization ↗
2,216
Medicare services
Top 40% in CA for hematology & oncology
650
Unique beneficiaries
$109
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~117 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
1,142 $111 $433
Hospital follow-up visit, high complexity
Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter.
747 $97 $308
Initial hospital admission, high complexity
Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter.
184 $138 $599
New patient office visit, complex (60-74 min) 76 $141 $615
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
67 $99 $322
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$307,477
Total received (2018-2024)
Avg $43,925/year across 7 years
Top 4% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
407
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$276,627 (90.0%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$26,665 (8.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,185 (1.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$11,663
2023
$10,332
2022
$22,139
2021
$13,130
2020
$19,945
2019
$114,273
2018
$115,995

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$10,571
AstraZeneca Pharmaceuticals LP
$244
PFIZER INC.
$191
Novartis Pharmaceuticals Corporation
$62
BeiGene USA, Inc.
$60
Dendreon Pharmaceuticals LLC
$52
Merck Sharp & Dohme LLC
$45
Lilly USA, LLC
$44
Janssen Biotech, Inc.
$35
Celgene Corporation
$33
ABBVIE INC.
$33
SpringWorks Therapeutics, Inc.
$32
SOBI, INC
$31
Mirati Therapeutics, Inc.
$30
Daiichi Sankyo Inc.
$28
Alexion Pharmaceuticals, Inc.
$27
Gilead Sciences, Inc.
$25
Incyte Corporation
$23
Janssen Pharmaceuticals, Inc
$22
GlaxoSmithKline, LLC.
$21
Astellas Pharma US Inc
$20
Sumitomo Pharma America, Inc.
$19
PharmaEssentia USA Corporation
$14
Top 3 companies account for 94.4% of 2024 payments
All-time payments by company (2018-2024) ›
Genentech USA, Inc.
$102,026
E.R. Squibb & Sons, L.L.C.
$83,717
Celgene Corporation
$43,910
Merck Sharp & Dohme Corporation
$20,321
Pharmacyclics LLC, An AbbVie Company
$18,089
Bayer HealthCare Pharmaceuticals Inc.
$9,925
Janssen Biotech, Inc.
$7,580
Lilly USA, LLC
$6,193
Ipsen Biopharmaceuticals, Inc
$5,821
PFIZER INC.
$2,986
AstraZeneca Pharmaceuticals LP
$2,316
Novartis Pharmaceuticals Corporation
$1,691
Astellas Pharma US Inc
$940
GlaxoSmithKline, LLC.
$262
Novocure GmbH
$200
Seagen Inc.
$153
Teleflex LLC
$150
United Therapeutics Corporation
$100
Puma Biotechnology, Inc.
$95
SERVIER PHARMACEUTICALS LLC
$75
SANOFI-AVENTIS U.S. LLC
$70
Takeda Pharmaceuticals U.S.A., Inc.
$70
BeiGene USA, Inc.
$60
Dendreon Pharmaceuticals LLC
$52
Gilead Sciences, Inc.
$51
AVEO Pharmaceuticals, Inc.
$46
Incyte Corporation
$46
Merck Sharp & Dohme LLC
$45
Karyopharm Therapeutics Inc.
$42
Sumitomo Pharma America, Inc.
$37
ABBVIE INC.
$33
SpringWorks Therapeutics, Inc.
$32
SOBI, INC
$31
Myriad Genetic Laboratories, Inc.
$31
Mirati Therapeutics, Inc.
$30
Daiichi Sankyo Inc.
$28
Alexion Pharmaceuticals, Inc.
$27
Amgen Inc.
$26
TESARO, Inc.
$25
EMD Serono, Inc.
$24
Janssen Pharmaceuticals, Inc
$22
GENZYME CORPORATION
$21
Bayer Healthcare Pharmaceuticals Inc.
$20
Exelixis Inc.
$18
Tactile Systems Technology Inc
$15
PharmaEssentia USA Corporation
$14
Medtronic USA, Inc.
$14
Top 3 companies account for 74.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AUGTYRO · Abraxane · Alecensa · Aliqopa · Avastin · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · ELITEK · ELREXFIO · ENHERTU · ERLEADA · Enhertu · FOTIVDA · Fabhalta · Flexitouch Plus · GAZYVA · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · KYPHON Balloon Kyphoplasty · LUTATHERA · LYNPARZA · MANTA · NINLARO · Nerlynx · Nubeqa · OGSIVEO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Onivyde · PADCEV · PIQRAY · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · REBLOZYL · ROZLYTREK · RYBREVANT · RYDAPT · Revlimid · SCEMBLIX · Stivarga · TECENTRIQ · TIBSOVO · TUKYSA · Tarceva · Trodelvy · ULTOMIRIS · UNITUXIN · VENCLEXTA · VERZENIO · VONJO · XPOVIO · XTANDI · ZEJULA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (90%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for hematology & oncology in CA.

Looking for a hematology & oncology specialist in Rancho Cucamonga?
Compare hematology & oncology specialists in the Rancho Cucamonga area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
53
Per 100K population
2.4
County median income
$82,184
Nearest hospital
KAISER FOUNDATION HOSPITAL FONTANA/ONTARIO
5.6 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Ebrahimi is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 4% of CA peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Ebrahimi experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Ebrahimi performed 1,142 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ebrahimi receive payments from pharmaceutical companies?
Yes. Dr. Ebrahimi received a total of $307,477 from 47 companies across 407 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ebrahimi's costs compare to other hematology & oncology specialists in Rancho Cucamonga?
Dr. Ebrahimi's average Medicare payment per service is $109. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ebrahimi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →